Incyte (INCY) Current Assets (2010 - 2026)
Incyte's (INCY) quarterly Current Assets came in at $6.0 billion in Q2 2026, up 65.4% YoY from $3.6 billion in Q2 2025, and up 9.89% on a QoQ basis from $5.5 billion in Q1 2026.
Incyte (INCY) Current Assets (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Current Assets data on file, last reported at $6.0 billion in Q2 2026.
- Quarterly Current Assets rose 65.4% year-over-year to $6.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.0 billion (up 65.4% YoY) and the FY2025 annual result came in at $5.0 billion, up 55.11% from the prior year.
- Current Assets grew to $6.0 billion in Q2 2026, from $5.5 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $6.0 billion in Q2 2026 to a low of $2.6 billion in Q2 2024.
- A 5-year average of $4.1 billion and a median of $4.0 billion in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets slumped 39.8% — and 2026, when it soared 65.4%.
- Tracing INCY's Current Assets over 5 years: stood at $4.1 billion in 2022, then grew by 13.5% to $4.6 billion in 2023, then slumped by 30.27% to $3.2 billion in 2024, then soared by 55.11% to $5.0 billion in 2025, then gained by 19.96% to $6.0 billion in 2026.
- The last three Current Assets figures came in at $6.0 billion (Q2 2026), $5.5 billion (Q1 2026), and $5.0 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 6.03 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.03 Bn |
| Mar 31, 2026 | 5.48 Bn |
| Dec 31, 2025 | 5.02 Bn |
| Sep 30, 2025 | 4.28 Bn |
| Jun 30, 2025 | 3.64 Bn |
| Mar 31, 2025 | 3.51 Bn |
| Dec 31, 2024 | 3.24 Bn |
| Sep 30, 2024 | 2.81 Bn |
| Jun 30, 2024 | 2.57 Bn |
| Mar 31, 2024 | 4.85 Bn |
| Dec 31, 2023 | 4.65 Bn |
| Sep 30, 2023 | 4.40 Bn |
| Jun 30, 2023 | 4.26 Bn |
| Mar 31, 2023 | 3.97 Bn |
| Dec 31, 2022 | 4.09 Bn |
| Sep 30, 2022 | 3.82 Bn |
| Jun 30, 2022 | 3.63 Bn |
| Mar 31, 2022 | 3.29 Bn |
| Dec 31, 2021 | 3.12 Bn |
| Sep 30, 2021 | 2.92 Bn |